TY - JOUR
T1 - A novel solid-in-oil nanosuspension for transdermal delivery of diclofenac sodium
AU - Piao, Hongyu
AU - Kamiya, Noriho
AU - Hirata, Akihiko
AU - Fujii, Takeru
AU - Goto, Masahiro
N1 - Funding Information:
The present work was supported in part by the 21st Century COE Program BFunctional Innovation of Molecular Informatics^ from the Ministry of Education, Culture, Science, Sports and Technology of Japan (to M.G.). We would like to thank Mr. Hideki Horiuchi, a glassworker, for his skill in preparing specific Franz-type diffusion cells.
PY - 2008/4
Y1 - 2008/4
N2 - Purpose. We formulated a solid-in-oil nanosuspension (SONS) as a novel transdermal delivery carrier for diclofenac sodium (DFNa). The basic transdermal characteristics of the SONS were evaluated using a Yucatan micropig (YMP) skin model. Methods. DFNa-sucrose erucate (i.e. surfactant) complexes were prepared via the formation of a water-in-oil emulsion. The complexes were suspended in isopropyl myristate (IPM) to form a SONS. The basic transdermal characteristics of the SONS were examined using full-thickness YMP dorsal skin in a Franz-type diffusion cell. DFNa powder suspended in IPM without complex formation was used as a control. The effect of the weight ratio of surfactant to DFNa on DFNa penetration of the skin was evaluated. Results. DFNa was successfully dispersed into IPM as a nanosized suspension via complex formation with sucrose erucate. The resultant SONS increased the permeability flux of DFNa across the YMP skin by up to 3.8-fold compared with the control. The size of the SONS depended on the weight ratio of the surfactant to DFNa. The optimal weight ratio for the highest DFNa permeation was 8.8, at which point the mean diameter of the SONS was 14.4 nm. Conclusion. The SONS formulation can enhance the percutaneous absorption of DFNa.
AB - Purpose. We formulated a solid-in-oil nanosuspension (SONS) as a novel transdermal delivery carrier for diclofenac sodium (DFNa). The basic transdermal characteristics of the SONS were evaluated using a Yucatan micropig (YMP) skin model. Methods. DFNa-sucrose erucate (i.e. surfactant) complexes were prepared via the formation of a water-in-oil emulsion. The complexes were suspended in isopropyl myristate (IPM) to form a SONS. The basic transdermal characteristics of the SONS were examined using full-thickness YMP dorsal skin in a Franz-type diffusion cell. DFNa powder suspended in IPM without complex formation was used as a control. The effect of the weight ratio of surfactant to DFNa on DFNa penetration of the skin was evaluated. Results. DFNa was successfully dispersed into IPM as a nanosized suspension via complex formation with sucrose erucate. The resultant SONS increased the permeability flux of DFNa across the YMP skin by up to 3.8-fold compared with the control. The size of the SONS depended on the weight ratio of the surfactant to DFNa. The optimal weight ratio for the highest DFNa permeation was 8.8, at which point the mean diameter of the SONS was 14.4 nm. Conclusion. The SONS formulation can enhance the percutaneous absorption of DFNa.
UR - http://www.scopus.com/inward/record.url?scp=43349108297&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43349108297&partnerID=8YFLogxK
U2 - 10.1007/s11095-007-9445-7
DO - 10.1007/s11095-007-9445-7
M3 - Article
C2 - 17896098
AN - SCOPUS:43349108297
SN - 0724-8741
VL - 25
SP - 896
EP - 901
JO - Pharmaceutical Research
JF - Pharmaceutical Research
IS - 4
ER -